LCM
CYTK icon

Landscape Capital Management’s Cytokinetics CYTK Stock Holding History

Landscape Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,477
Closed -$730K – 700
2024
Q2 		$730K Buy
+13,477
New +$813K 0.06% 394
2018
Q1 		– Sell
-32,237
Closed -$263K – 511
2017
Q4 		$263K Buy
+32,237
New +$366K 0.02% 508

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Landscape Capital Management's CYTK Position: Q3 2024 in Review

Landscape Capital Management sold out of Cytokinetics (CYTK) in Q3 2024, closing a stake of 13,477 shares — an estimated $730K sold.

Landscape Capital Management first reported a position in CYTK in Q4 2017 and held it in 2 quarters. The position peaked at $730K in Q2 2024. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

  • Landscape Capital Management reported no remaining Cytokinetics position as of Q3 2024 after selling out during the quarter.
  • Landscape Capital Management sold 13,477 Cytokinetics shares in Q3 2024, an estimated $730K.
  • Landscape Capital Management first reported a position in Cytokinetics in Q4 2017 and held it in 2 quarters.
  • Landscape Capital Management's Cytokinetics position peaked at $730K in Q2 2024.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on Landscape Capital Management's 13F filing for Q3 2024, filed 8 Nov 2024.